Claims
- 1. A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals an amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form effective to inhibit effects of exogenous neurotropic or neurotoxinic products.
- 2. The method of claim 1, characterized in that the thienylcyclohexylamine is combined with at least one substance chosen from anticholinergic, anticonvulsive substances and substances which reactivate cholinesterases.
- 3. The method of claim 2, characterized in that the anticholinergic substance is chosen from atropine, scopolamine, atropine N-oxide, dihexyverine and tiemonium methylsulphate.
- 4. The method of claim 2, characterized in that the anticonvulsive substance is chosen from the following substances: phenobarbital, primidone, the benzodiazepins, carbamazepine, ethosuximide, phenytoin, sodium valproate, progabide, gabapentin, vigabatrin and loprazolam.
- 5. The method of claim 4, characterized in that the anticonvulsive substance is a benzodiazepin chosen from clonazepam, clobazam, diazepam and prodiazepam.
- 6. The method of claim 2, characterized in that the substance which reactivates cholinesterases is chosen from the following substances: pralidoxime, obidoxime and HI6.
- 7. The method of claim 1, characterized in that the thienylcyclohexylamine is combined with at least one anticholinergic substance, at least one anticonvulsive substance and at least one substance which reactivates cholinesterases.
- 8. The method of claim 1, characterized in that the thienylcyclohexylamine is combined with a reversible cholinesterase inhibitor intended to be administered before exposure to the neurotoxic products or those containing neurotoxin.
- 9. The method of claim 1, characterized in that the reversible cholinesterase inhibitor is chosen from pyridostigmine, physostigmine.
- 10. The method of claim 1, characterized in that 2-methyl-1-(1-piperidinyl)-1-(2-thienyl) cyclohexane, in substantially pure racemic, diastereoisomeric or enantiomeric form, is administered within two hours following intoxication with neurotoxic products or those containing neurotoxin.
- 11. A composition for inhibiting exogenous neurotropic or neurotoxinic effects comprising an exogenous neurotoxic or neurotoxinic inhibitorily effect amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form and at least one other pharmaceutical capable of limiting said effects chosen from anticholinergic substances and substances which reactivate cholinesterases and an inert pharmaceutical carrier.
- 12. A composition of claim 11 wherein that the anticholinergic substance is chosen from atropine, scopolamine, atropine N-oxide, dihexyverine and tiemonium methylsulphate.
- 13. A composition of claim 11 wherein the substance which reactivates cholinesterases is chosen from pralidoxime, obidoxime, HI6.
- 14. The the composition of claim 11 wherein the substance is a reversible cholinesterase inhibitor.
- 15. The the composition of claim 14 wherein the substance is pyridostigmine or physostigmine.
Priority Claims (2)
Number |
Date |
Country |
Kind |
96 14996 |
Dec 1996 |
FR |
|
97 07361 |
Jun 1997 |
FR |
|
FIELD OF THE INVENTION
This application is a 371 of PCT/FR97/02219, filed on May 12, 1997.
The present invention relates to the use of a thienylcyclohexylamine, by itself or in combination with other substances with a pharmaceutical activity, for the preparation of a medicament intended to limit or inhibit the effects due to neurotoxic products or those containing neurotoxin. The invention also relates to a product containing a thienylcyclohexylamine and at least one anticholinergic, anticonvulsive or cholinesterase reactivator, and a pharmaceutical composition containing it. This product is also particularly useful for its activity of limiting or inhibiting the effects due to neurotoxic products or those containing neurotoxin.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/FR97/02219 |
|
WO |
00 |
1/11/1999 |
1/11/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/24434 |
6/11/1998 |
WO |
A |
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5179109 |
Kamenka et al. |
Jan 1993 |
|
5604255 |
Rice et al. |
Feb 1997 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0317953 |
May 1989 |
EP |
9005524 |
May 1990 |
FR |
Non-Patent Literature Citations (1)
Entry |
Cross et al., Abstract to “Neuroprotective activity of chlormethiazole following transient forebrain ischemia in the gerbil”, Br. J. Pharmacol. 104(2), pp. 406-411, 1991. |